Beam Therapeutics' second quarter is the print where the company finally crossed the line from "early-stage base editing platform" to "company with a global pivotal cohort enrolling in two indications and a US biologics license application on the calendar by year-end." In July, two months after reporting 60 mg single-dose data from 29 alpha-1 antitrypsin deficiency (AATD) patients that pushed every subject above the 11 micromolar (µM) protective threshold with up to 12 months of follow-up, Beam dosed the first patient in the global pivotal cohort of BEAM-302 in AATD-associated lung disease. Dosing is now also complete in all adult and adolescent patients in the BEACON trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD), and a US Biologics License Application is now expected as early as year-end 2026.
Q2 financials were a quiet back-office story: a $122.7 million GAAP net loss ($1.18 per share, GAAP basic and diluted) on a $95.1 million research and development (R&D) line that was down 6.5% year over year (YoY) and license-and-collaboration revenue of just $490,000, against a $1.2 billion cash and marketable-securities position that funds the company into mid-2029. The investment case turns on whether the next twelve months of data events re-rate the equity.
The open question: can BEAM-302's late-breaking European Respiratory Society (ERS) Congress update on September 5-9, 2026, and risto-cel's US BLA submission by year-end, crystallize the platform's value at a moment when the market is paying roughly $2.8 billion for $1.2 billion of cash and zero approved products? Falsifiable by a single ERS data cut and a BLA acceptance letter.